Eleven Biotherapeutics, Inc. (EBIO) Sees Large Volume Increase
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) saw strong trading volume on Friday . 2,978,328 shares traded hands during trading, an increase of 1,608% from the previous session’s volume of 174,420 shares.The stock last traded at $1.65 and had previously closed at $1.19.
Several research analysts recently issued reports on the stock. ValuEngine cut shares of Eleven Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, June 13th. Zacks Investment Research raised shares of Eleven Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th.
The stock has a 50-day moving average of $1.29 and a 200-day moving average of $1.63. The stock has a market capitalization of $25.40 million, a PE ratio of 15.14 and a beta of 3.37.
Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter. Eleven Biotherapeutics had a net margin of 11.28% and a return on equity of 4.26%. Equities analysts predict that Eleven Biotherapeutics, Inc. will post ($1.75) EPS for the current fiscal year.
A number of large investors have recently modified their holdings of EBIO. Virtu KCG Holdings LLC bought a new stake in Eleven Biotherapeutics in the 2nd quarter valued at about $175,000. Spark Investment Management LLC bought a new stake in Eleven Biotherapeutics in the 2nd quarter valued at about $148,000. Finally, Vanguard Group Inc. lifted its position in Eleven Biotherapeutics by 17.4% in the 2nd quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 30,600 shares during the last quarter. Hedge funds and other institutional investors own 5.05% of the company’s stock.
Eleven Biotherapeutics Company Profile
Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.